Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 10/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 0.63 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714053 | 0.91 | TTR (0.84) | TTRMAOAPTGER4NPC1RAB9A | |
| SCHEMBL10623602 | 0.91 | TTR (0.83) | TTRMAOAPTGER4NPC1RAB9A | |
| SCHEMBL1787556 | 0.90 | TTR (1.00) | TTRMAOANPC1RAB9AKDM4E | |
| SCHEMBL11471734 | 0.90 | TTR (0.81) | TTRMAOAPTGER4NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL11367851 | 0.89 | TTR (0.97) | TTRMAOANPC1RAB9AKDM4E | |
| SCHEMBL11322640 | 0.88 | TTR (0.80) | TTRMAOAPTGER4NPC1RAB9A | |
| SCHEMBL27733179 | 0.87 | TTR (0.77) | TTRMAOAPTGER4NPC1RAB9A | |
| Xanthone SCHEMBL28077164 | 0.86 | TTR (0.75) | TTRMAOANPC1RAB9AKDM4E | |
| SCHEMBL3964072 | 0.85 | TTR (0.74) | TTRMAOAPTGER4NPC1RAB9A | |
| SCHEMBL11860391 | 0.85 | TTR (0.74) | TTRMAOAPTGER4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9772552-B2 | Thiosulfate polymer compositions and articles | EASTMAN KODAK COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9005878-B2 | Forming patterns using thiosulfate polymer compositions | EASTMAN KODAK COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-8916336-B2 | Patterning method using thiosulfate polymer and metal nanoparticles | EASTMAN KODAK COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140287349-A1 | THIOSULFATE POLYMER COMPOSITIONS AND ARTICLES | BANK OF AMERICA, N.A., AS AGENT | 2014-09-25 | — | — | US | disclosed |
| US-20140287364-A1 | PATTERNING METHOD USING THIOSULFATE POLYMER AND METAL NANOPARTICLES | BANK OF AMERICA, N.A., AS AGENT | 2014-09-25 | — | — | US | disclosed |
| US-20140287365-A1 | FORMING PATTERNS USING THIOSULFATE POLYMER COMPOSITIONS | BANK OF AMERICA, N.A., AS AGENT | 2014-09-25 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| CN-1839135-A | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-09-27 | — | — | CN | disclosed |
| WO-2006069275-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006069277-A1 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
| EP-1644373-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-12 | — | — | EP | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
| WO-2005003131-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
| US-3957989-A | ADMINISTERING | RICHARDSON-MERRELL INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135524-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885PTGER4 137/4885 |
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885PTGER4 137/4885 |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885PTGER4 137/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885PTGER4 137/4885 |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | TTR 2536/4885MAOA 948/4885PTGER4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.